StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Nelfinavir

HCID 64143
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
159989-64-7
Standard-SMILES
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
InChIKey
QAGYKUNXZHXKMR-HKWSIXNMSA-N
Summenformel
C32H45N3O4S
Durchschnittliche Molmasse
567,8 g/mol
Monoisotopische Masse
567,3130781

Überblick

Nelfinavir is an aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties. It has a role as an antineoplastic agent and a HIV protease inhibitor. It is a member of benzamides, an organic heterobicyclic compound, a member of phenols, a secondary alcohol, an aryl sulfide and a tertiary amino compound. It is a conjugate base of a nelfinavir(1+).

Namen und Bezeichner

Bevorzugter Name
Nelfinavir
IUPAC
(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamide
Englischer Name
NELFINAVIR
Summenformel
C32H45N3O4S
Molmasse
567.78

Namen und Synonyme

nelfinavir159989-64-7nelfinavirum(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylsulfanylbutyl]-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamideHO3OGH5D7INSC-747167CHEBI:7496DTXSID50350803-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2-(2S*,3S*),3-alpha,4a-beta,8a-beta))-(3S,4aS,8aS)-N-tert-butyl-2-((2R,3R)-2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-phenylsulfanylbutyl)-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline-3-carboxamideRefChem:57161DTXCID3015080
Weitere Namen anzeigen
AG 1341nefinavirNELFINAVIR-12Nelfinavir D58a-beta))-a-betNELFINAVIR iMpurityNELFINAVIR USP/EP/BPNelfinavir (AG-1341)Nelfinavir (AG-1343)
J05AE04ViraceptViracept (TN)1ohrNELFINAVIR MESYLATE AG1343Nelfinavir (INN)AG-1343Met-SDF-1.beta. & Nelfinavir

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
5,7
Polarare Oberfläche (TPSA)
127 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
10
Schwere Atome
40
Formalladung
0
Komplexität
829

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LogP · 2 Einträge

6

4.0

Solubility · 2 Einträge

Slightly soluble

1.91e-03 g/L

Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Infective Agents; Antiviral Agents; Anti-HIV Agents; Anti-Retroviral Agents; HIV Protease Inhibitors
Melting Point349.84 °C
Physical DescriptionSolid

Physikochemische Eigenschaften

Schmelzpunkt
185 · 185-186 °C
Siedepunkt
786.8 · 786.8±60.0 °C(Predicted)
Dichte
1.22 · 1.22±0.1 g/cm3(Predicted)
storage temp.
2 · under inert gas (nitrogen or Argon) at 2–8 °C

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Some degree of serum aminotransferase elevation occurs in a high proportion of patients taking nelfinavir containing antiretroviral regimens. Moderate-to severe elevations in serum aminotransferase levels (>5 times the upper limit of normal) are found in only 3% to 10% of patients, although rates may be higher in patients with HIV-HCV coinfection. These elevations are usually asymptomatic and self-limited and can resolve even with continuation of the medication. Clinically apparent acute liver injury due to nelfinavir is rare. The few cases that have been reported have arisen after 1 to 8 weeks of starting nelfinavir, and the pattern of serum enzyme elevations has not been reported, but is likely to have been hepatocellular (Case 1). Signs of hypersensitivity (fever, rash, eosinophilia) can occur as can autoantibody formation but these features are not very prominent. The acute liver injury due to nelfinavir is usually self-limited, but it can be severe, and isolated cases of acute liver failure have been reported to the sponsor, although not in great detail. In HBV or HCV coinfected patients, some instances appear to be due to exacerbation of the underlying chronic liver disease, perhaps as a result of sudden immune reconstitution. Nelfinavir therapy has not been clearly linked to lactic acidosis and acute fatty liver that is reported in association with several nucleoside analogue reverse transcriptase inhibitors used to treat HIV infection.

Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

nelfinavir

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

Toxizität
rat,LD,oral,> 5gm/kg (5000mg/kg),Toxicologist. Vol. 42, Pg. 55, 1998.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingNelfinavir in serum is extensively protein-bound (>98%).
Pharmacodynamics · 1 Eintrag

Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Mechanism of Action · 1 Eintrag

HIV viral protease is an important enzyme for HIV maturation and pathogenicity since HIV produces its structural and key proteins in the form of a polyprotein that needs to be cleaved by a protease. HIV protease is synthesized as part of the Gag-pol polyprotein, where Gag encodes for the capsid and matrix protein to form the outer protein shell, and Pol encodes for the reverse transcriptase and integrase protein to synthesize and incorporate its genome into host cells. The Gag-pol polyprotein undergoes proteolytic cleavage by HIV protease to produce 66 molecular species which will assume conformational changes to become fully active. Inhibition of protease, therefore, prevents HIV virion from fully maturing and becoming infective. Nelfinavir is a competitive inhibitor of the HIV protease by reversibly binding to the active site of the enzyme, preventing it from interacting with its substrate to produce mature and infectious viral particles.

Biological Half-LifeThe terminal half-life in plasma was typically 3.5 to 5 hours.
Metabolism/Metabolites · 2 Einträge

Unchanged nelfinavir comprised 82-86% of the total plasma radioactivity after a single oral 750 mg dose of 14C-nelfinavir. In vitro, multiple cytochrome P-450 enzymes including CYP3A and CYP2C19 are responsible for the metabolism of nelfinavir. One major and several minor oxidative metabolites were found in plasma. The major oxidative metabolite has in vitro antiviral activity comparable to the parent drug.

Zugehörige Reaktionen

23
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 346872
HRID 346872als Produkt
Reaktionsgleichung von HRID 380731
HRID 380731als Edukt
Reaktionsgleichung von HRID 380732
HRID 380732als Edukt
Reaktionsgleichung von HRID 384737
HRID 384737als Edukt
Reaktionsgleichung von HRID 384738
HRID 384738als Edukt
Reaktionsgleichung von HRID 384739
HRID 384739als Edukt
Reaktionsgleichung von HRID 384740
HRID 384740als Edukt
Reaktionsgleichung von HRID 384741
HRID 384741als Edukt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
159989-64-7
PubChem CID
64143
DTXSID
DTXSID5035080
ChEMBL
CHEMBL584
ChEBI
CHEBI:7496
UNII
HO3OGH5D7I
Nikkaji
J1.642.472B
Löslichkeit
20.45 mg/mL · ≥ 20.45mg/mL in Ethanol
Aggregatzustand
Powder
pka
1 · pKa1 6.0; pKa2 11.06(at 25℃)
Farbe
White to off-white
Wasserlöslichkeit
7 g/L · 7g/L(temperature not stated)

Nelfinavir has known human metabolites that include 3,4-Dihydroxynelfinavir and Nelfinavir hydroxyl-t- butylamide.

FDA Pharmacological Classification · 6 Einträge

HO3OGH5D7I

NELFINAVIR

Mechanisms of Action [MoA] - HIV Protease Inhibitors

Established Pharmacologic Class [EPC] - Protease Inhibitor

Mechanisms of Action [MoA] - Cytochrome P450 3A Inhibitors

Nelfinavir is a Protease Inhibitor. The mechanism of action of nelfinavir is as a HIV Protease Inhibitor and Cytochrome P450 3A Inhibitor.

MeSH Pharmacological ClassificationInhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
Absorption, Distribution and Excretion · 4 Einträge

Well absorbed following oral administration.

The majority (87%) of an oral 750 mg dose containing 14C-nelfinavir was recovered in the feces; fecal radioactivity consisted of numerous oxidative metabolites (78%) and unchanged nelfinavir (22%). Only 1–2% of the dose was recovered in urine, of which unchanged nelfinavir was the major component.

The apparent volume of distribution following oral administration of nelfinavir was 2-7 L/kg.

Oral clearance estimates after single doses (24-33 L/h) and multiple doses (26-61 L/h) indicate that nelfinavir is a drug with medium to high hepatic bioavailability.

Cellular LocationsCytoplasm

Verwendung und Herstellung

UsesUse (kg) in Switzerland (2009): >10

Anwendungen

VerwendenAntiviral.

Ergänzende Hinweise

DefinitionChEBI: An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.